[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100472793":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":11,"centralContacts":20,"locations":26,"responsibleParty":43,"collaborators":11,"id":45,"slug":46,"hasResults":47,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":11,"eligibilityCriteria":51,"healthyVolunteers":47,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":11,"studyType":58,"phases":59,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":29,"whyStopped":11,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":79},{"fullName":5,"class":6},"Shenzhen Geno-Immune Medical Institute","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"bi-4SCAR-CD19\u002F79b T Cell Therapy for CD19 and\u002For CD79b positive B cell malignancies","EXPERIMENTAL",null,[13],"Biological: bi-4SCAR CD19\u002F79b T cells",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"BIOLOGICAL","bi-4SCAR CD19\u002F79b T cells","Infusion of bi-4SCAR-CD19\u002F79b T cells at 10\\^6 cells\u002Fkg body weight via IV",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},"Lung-Ji Chang, PhD","CONTACT","+86 0755-86573763","c@szgimi.org",[27],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"Shenzhen Geno-immune Medical Institute","RECRUITING","Shenzhen","Guangdong","518000","China","CN",{"type":36,"coordinates":37},"Point",[38,39],114.0683,22.54554,{"lat":39,"lon":38},[42],{"name":22,"role":23,"phone":24,"phoneExt":11,"email":25},{"type":44,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100472793","phase-1-cd1979b-bi-specific-car-t-cell-therapy-100472793",false,"NCT05436509","CD19\u002F79b Bi-specific CAR-T Cell Therapy","CD19\u002F79b Bi-specific CAR-T Cells Targeting B Cell Malignancies","Inclusion Criteria:\n\n1. age older than 6 months.\n2. malignant B cell surface expression of CD19 or CD79b molecules.\n3. the KPS score over 80 points, and survival time is more than 1 month.\n4. greater than Hgb 80 g\u002FL.\n5. no contraindications to blood cell collection.\n\nExclusion Criteria:\n\n1. accompanied with other active diseases and difficult to assess patient response.\n2. bacterial, fungal, or viral infection, unable to control.\n3. living with HIV.\n4. active HBV or HCV infection.\n5. pregnant and nursing mothers.\n6. under systemic steroid treatment within a week of the treatment.\n7. prior failed CD19 and CD79b CAR-T treatment.","ALL","6 Months","75 Years",{"count":56,"type":57},60,"ESTIMATED","INTERVENTIONAL",[60,61],"PHASE1","PHASE2","The purpose of this study is to assess the feasibility, safety and efficacy of CD19\u002F79b bi-specific CAR-T cell therapy in patients with CD19 and\u002For CD79b positive B cell malignancies. Another goal of the study is to learn more about the safety and function of the anti-CD19\u002F79b bi-specific CAR-T cells and their persistency in patients.",[64],"B Cell Malignancies",[66,67,68,69],"CAR-T","B cell Malignancies","CD19","CD79b","2026-06-18",{"date":72,"type":73},"2026-06-23","ACTUAL",{"date":75,"type":73},"2026-06-01",{"date":77,"type":57},"2030-12-31",{"name":5,"class":6},1]